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ELUSIDASI POTENSI DIAGNOSTIK DAN TERAPEUTIK APTAMER RNA 
TERHADAP HUMAN PITUITARY TUMOUR TRANSFORMING GENE 1 
 
ABSTRAK 
 
Aptamer asid nukleik merupakan sejenis unsur pengecaman molekul yang 
mampu berinteraksi dengan sasaran pada spesifisiti dan keafinan yang tinggi. Kajian 
ini bertujuan untuk menghasilkan aptamer RNA terhadap “Human Pituitary Tumor 
Transforming Gene 1” (PTTG1) yang mempunyai potensi berfungsi sebagai unsur 
diagnostik dan terapeutik. Gen PTTG1 terlebih dulu diklonkan ke vektor pET14b untuk 
menggabungkan jujukan teg 6X histidin pada gen tersebut. Pengekspresan dan 
purifikasi protein tersebut dilaksanakan menggunakan strain E. coli Rosetta 
2(DE3)pLysS. Identiti protein disahkan dalam blot ‘Western’ menggunakan antibodi 
monoklon anti-PTTG1. Analisis spektra pendarfluor intrinsik dan analisis interaksi 
PTTG1 dengan GST-p53 memberi tanda-tanda pelipatan protein yang berjaya. 11 
kitaran SELEX dilaksanakan mengunakan dua jenis strategi pemetakan yang dikesan 
memberi tanda-tanda pemerkayaan. Penjujukan himpunan asid nukleik kitaran 8 
menunjukkan kehadiran aptamer (SECURA-3) yang menunjukkan interaksi dengan 
PTTG1. SECURA-3 mempunyai pemalar pemisahan yang dianggarkan pada 16.41 ± 
6.4 nM. SECURA-3 digunakan untuk menghasilkan asai diagnostik berasaskan 
aptamer iaitu ALISA, blot titik berasaskan aptamer, blot ‘Western’ berasaskan 
aptamer, dan “aptahistostaining”. SECURA-3 yang ditambah dengan ekor poli-A pada 
hujung 3’nya untuk dilabel dengan biotin melalui hibridisasi dengan oligo dT yang 
berlabelkan biotin. Aptamer SECURA-3 menunjukkan pengesanan PTTG1 sehingga 
0.0256 nM dalam ujian ALISA langsung dan dengan konfigurasi sandwich pula, 
SECURA-3 menunjukkan pengesanan PTTG1 sehingga 3.2 nM dengan aptamer 
xvii 
 
sebagai ejen penangkap dan 16 nM dengan aptamer sebagai ejen pengesanan. Dalam 
asai blot titik berasaskan aptamer, sehingga 2.5 pmol protein PTTG1 berjaya dikesan. 
SECURA-3 juga berjaya mengesan PTTG1 yang dimurnikan serta dalam lisat sel 
HeLa dan MCF-7 di asai blot ‘Western’ berasaskan aptamer. Selain itu, SECURA-3 
berjaya mengesan PTTG1 dengan penembusan yang lebih baik berbanding dengan 
antibodi monoklon dalam blok paraffin sel difiksatif formalin HeLa dan MCF-7. 
Seterusnya, dalam meneliti potensi terapeutik SECURA-3, ujian antagonis dengan 
jujuran CXCR2 yang ditransaktifkan oleh PTTG1 dilaksanakan. SECURA-3 memberi 
kesan antagonis terhadap urutan CXCR2 dalam asai ikatan bersaing in vitro 
berturaskan nitroselulosa. Sehubungan dengan itu, potensi terapeutik dikaji dalam sel 
HeLa berlandaskan jujuran CXCR2 yang sama dalam asai pelapor dwi lusiferase dan 
aptamer SECURA-3 sebagai agen antagonis. Kesan antagonis berkeperluan dos 
seterusnya ditunjukkan SECURA-3 dengan mengurangkan aktiviti lusiferase relatif 
berbanding dengan RNA olokan menggunakan asai pelapor tersebut dalam sel HeLa. 
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ELUCIDATING THE DIAGNOSTIC AND THERAPEUTIC POTENTIAL OF 
AN RNA APTAMER AGAINST HUMAN PITUITARY TUMOUR 
TRANSFORMING GENE 1 
 
 
ABSTRACT 
 
 
Nucleic acid aptamers are a class of molecular recognition elements capable of 
target interaction at high specificity and affinity. This study was aimed to generate an 
RNA aptamer against the Human Pituitary Tumour Transforming Gene 1 (PTTG1) 
oncoprotein which can serve as a potential diagnostic and therapeutic tool. PTTG1 
gene was first cloned into the pET14b vector to incorporate the small 6X Histidine tag. 
Protein expression and purification ensued with the E. coli Rosetta 2(DE3)pLysS strain 
under the urea denaturing method. The protein identity was confirmed by western blot 
using monoclonal anti-PTTG1 antibody. Intrinsic florescence spectra analysis and 
GST-pulldown interaction analysis with GST-p53 conferred signs of successful protein 
refolding. 11 SELEX cycles with dual partitioning strategy were performed with 
positive indication of enrichment. Sequencing of the cycle 8 pool revealed a putative 
aptamer (SECURA-3) which depicted binding to PTTG1. SECURA-3 had a 
dissociation constant estimated at 16.41 ± 6.4 nM. SECURA-3 was employed for 
development of aptamer-based diagnostic assays namely ALISA, aptamer-based dot 
blot, aptamer based western blot and aptahistostaining. SECURA-3 was extended with 
a poly A-tail at the 3’-end to functionally labelled with the biotin by hybridization with 
the biotin labelled oligo dT sequence. SECURA-3 aptamer demonstrated detection of 
up to 0.0256 nM PTTG1 in the direct ALISA assay and with the sandwich 
configuration, SECURA-3 demonstrated detection of PTTG1 up to 3.2 nM with the 
aptamer as the capturing agent and 16 nM with the aptamer as the detection agent. In 
xix 
 
the aptamer-based dot blot assay, up to 2.5 pmol PTTG1 was detected. SECURA-3 
successful detected purified PTTG1 in aptamer assisted western blot as well as in the 
HeLa and MCF-7 cell lysates. In the aptahistostaining assay, SECURA-3 successfully 
detected PTTG1 with better penetration compared to the monoclonal antibody in the 
HeLa and MCF-7 formalin fixed paraffin embedded cell blocks. SECURA-3 
demonstrated antagonistic effects towards PTTG1 and the CXCR2 regulatory 
sequence in the in vitro competitive nitrocellulose filter binding assay. The antagonistic 
effect was further demonstrated in a dose dependent manner by decreased relative 
luciferase activity compared to the mock RNA under the luciferase reporter assay in 
HeLa cells. 
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CHAPTER 1 
INTRODUCTION 
1.1 Introduction to Aptamers 
One of the hallmarks in the field of applied sciences lies in translating research 
from bench to bedside. New pursuits in designing better and faster responses to 
upcoming threats are a core focus (Van Damme et al., 2018). Using combinatorial 
libraries in screening for potential ligands has been one research focus that lead to the 
development of diagnostic or therapeutic applications. One such combinatorial library 
is the nucleic acid combinatorial library which generates target binders called aptamers 
(Gold, 1995).  
Aptamers, termed after the Latin word ‘aptus’ which means ‘to fit’ and ‘meros’, 
which means ‘particle’ are single stranded nucleic acids that exhibits ligand binding 
phenotype with high affinity and specificity (Ellington et al., 1990). Aptamers has been 
generated over an extensive array of targets such as small metal ions and organic 
molecules, peptides, proteins, microorganisms, and cells. They have demonstrated 
dissociation constants in the low nanomolar and high picomolar levels (Nimjee et al., 
2017; Vance et al., 2014; Kensch et al., 2000). Additionally, they are capable of 
discriminating the target difference between a single amino acid mutation, a single 
functional group difference, target enantiomer or even conformational changes in the 
target (Chen et al., 2015; Zichel et al., 2012; Geiger et al., 1996; Jenison et al., 1994). 
The phenotype exhibited by the aptamers are dictated by the structural motifs such 
as stemloop, G‑quadruplex and pseudoknot (Hoinka et al., 2012; Patel, 1997). These 
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motifs collectively aid in the unique three dimensional structure of the aptamer that 
interacts with their target through either hydrogen bonding, hydrophobic interactions, 
electrostatic interactions, Van der Waals forces, base stacking or a combination of them 
(Rozenblum et al., 2016; Hermann et al., 2000; Patel, 1997). 
Molecular recognition elements are typically required to cater to the demands of 
various applications such as durability across a variety of sample conditions or specific 
assay dependent functionalization to name a few. In line with the demands, aptamers 
are subjectable to a myriad of modifications and labelling with functional groups,  
reporters or signalling compounds, and linkers as commonly applicable with standard 
oligonucleotide probes (Da Pieve et al., 2009). Several combinations of modifications 
can simultaneously be applied as well. For example, in the case of Macugen, the FDA 
approved commercialized RNA aptamer against age-related macular degeneration, the 
nuclease-resistant analogues, 2’-fluoropyrimidines, and 2’-O-methyl purine 
nucleosides were utilized (Ng et al., 2006). Additionally, Macugen was also modified 
with an inverted 3’ terminal nucleotide for added nuclease resistance and a 40 kDa 
polyethylene glycol at the 5’-end for improved aptamer retention in the body through a 
reduced renal filtration (Ng et al., 2006).  
1.2 Systematic Evolution of Ligands by Exponential Enrichment (SELEX) 
Aptamers are generated from a process called Systematic Evolution of Ligands by 
Exponential Enrichment (SELEX) (Tuerk et al., 1990). The key idea in SELEX lies in 
the directed evolution of sequences from an initial highly diverse pool of sequences 
which are subsequently deconvoluted into an enriched pool of sequences under selective 
pressure derived from the binding conditions such as target protein concentration, salt 
concentration and temperature. The enriched pool of sequences comprises the potential 
3 
 
binders that impart binding onto the target (Dunn et al., 2017). SELEX requires the use 
of a combinatorial library consisting of single stranded nucleic acids, whereby the 
library was designed to contain a randomized region in the middle flanked at the ends 
with a pair of conserved sequences for amplification. The sequence diversity of the 
combinatorial library is imparted by the length of randomized bases, thus giving birth 
to as many as 4n sequences where n is the length of the randomized region (Kopylov et 
al., 2000).  
A three-staged process holds basis to the fundamentals of SELEX (Figure 1.1) ;  
(i) incubation of the randomized oligonucleotide library with the target (ii) separation 
of the unbound sequences from the target-bound sequence (iii) amplification of the 
bound sequences (Dunn et al., 2017; Irvine et al., 1991). This iterative cycle is repeated 
under a selective pressure typically consisting of stringent binding and washing 
conditions such as varying ratios of target/nucleic acid competitor such as Salmon 
Sperm DNA or yeast tRNA to allow the propagation of the high affinity sequences 
amongst the weak binders (Marshall et al., 2000).  
With the foundations of SELEX in mind, various approaches have been made 
to tailor SELEX in order to fit the criteria and specific assay requirements set by the 
researcher. Cell-SELEX is a form of selection in which whole cells were used as a target 
to allow isolation of aptamers against surface biomolecules in their native conformation, 
with no prior knowledge of the surface biomarkers (Ohuchi, 2012). Capillary 
electrophoresis-SELEX utilizes differential rate of migration between the target-bound 
sequences and unbound sequences, thus minimizing the SELEX rounds to merely 2-4 
rounds  (Mosing et al., 2009). Cell internalization SELEX involves selection of 
aptamers capable of internalizing into the cells, thus creating a powerful tool in cancer 
targeted therapy (Gray et al., 2018; Yan et al., 2014) 
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Figure 1.1 The conventional SELEX cycle.  
The initial degenerate library (whereby the diversity is accounted for by the randomized 
sequences flanked by conserved sequences at both ends) is directly used for DNA 
aptamer selection or in vitro transcribed into RNA for RNA aptamer selection. The 
nucleic acid pool is then incubated with the target protein and the unbound nucleic acids 
are partitioned out. The bound nucleic acids will then be eluted from their target and 
subjected to amplification. In the amplification step, the eluted sequences are amplified 
by PCR for DNA aptamer or RT-PCR for RNA aptamer generation, thus obtaining the 
nucleic acid pool in the double stranded form for the use in the next SELEX cycle. A 
conversion process then takes place to convert the double stranded DNA into ssDNA 
pool in case of DNA aptamer generation. For RNA aptamer generation, in vitro 
transcription was carried out to convert the double stranded DNA into the RNA pool. 
This process occurs for 8 to 15 rounds after which the nucleic acids sequences will be 
analysed to unveil the putative aptamer sequences.  
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1.3 Advantages of Aptamers Over Antibodies 
As molecular recognition elements, aptamers are often compared to antibodies and are 
hence termed as ‘chemical antibodies’ (Chen et al., 2017; Jayasena, 1999). However, 
there are distinguishing differences between the aptamers and antibodies apart from 
their molecular construction.  
Aptamers are significantly smaller than antibodies in which a typical aptamer of 
100 nt has a size at about 30 kDa, while an antibody has a size of around 150 kDa (Zhou 
et al., 2017; Sun et al., 2014). This is especially helpful in terms of penetrability of 
aptamers such as across the blood-brain barrier (Monaco et al., 2017) and tissue 
penetration in immunostaining based applications (Zeng et al., 2010).  
The production of the aptamers are in a controlled biochemical setting which 
proves to be easier and without the potential batch-to-batch variation as compared to 
the biological requirement for antibody production (Marx, 2013). Furthermore, as a 
synthetic ligand, aptamers can be generated against targets that are toxic to cells 
(Rozenblum et al., 2016). Aptamers also reaps benefits in the heat stability aspect such 
as from reversible heat denaturation as well as a lower shipping cost relative to 
antibodies as it does not require cold-chain logistics (Dunn et al., 2017).  
As therapeutics, aptamers exhibit low to no immunogenicity when applied to 
humans and rodents (Eyetech Study Group, 2003). Furthermore, reversal of drug 
activity is possible with aptamers in therapeutic applications by administration of 
‘antidotes’ which are antisense oligonucleotides complementary to the aptamer binding 
domain (Rusconi et al., 2004). The structure of the active aptamer will be distorted from 
the ‘antidote’ binding and rendered inactive. However in comparison to antibodies, 
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aptamers remain to date an early technology that require further work and development 
to ensure growth within the next 25 years (Dunn et al., 2017). 
1.4 Aptamers in the Diagnostics Platform 
Aptamers holds vast potential in the diagnostics platform where some has achieved 
commercialisation. New England Biolabs uses a DNA aptamer as an inhibitor to their 
polymerase in their Hot Start Taq DNA polymerase (Cat No. M0496S and M0490S). 
Their Taq DNA polymerase is rendered active when the aptamer is released at higher 
temperatures thus catering for room temperature PCR component set up.  
For the agro-food industry, Neoventures Biotechnology Inc. commercialized 
their product OTA-Sense which detects for the presence of mycotoxin, Ochratoxin A, 
at parts per billion quantities usually found in contaminated wheat products (Cruz-
Aguado et al., 2008). The kit utilizes Terbium based-florescence which forms a cation 
bridge with the aptamer-ochratoxin complex and its florescence intensity is measured.  
Aptamers have also been developed to cater for human disease diagnostics as 
well. Sekisui Diagnostics, GmbH released their product, OLIGOBIND 
(https://www.sekisuidiagnostics.com/products/722-thrombin-activity-assay) which 
features an aptamer-based enzyme-capture florescent assay to detect true levels of 
active thrombin in vivo. This is especially important to diagnose patient predisposed to 
bleeding complications. The kit achieved detected picomolar levels of thrombin and 
showed a 100-fold selectivity to thrombin than prothrombin (Konigsbrugge et al., 2017; 
Muller et al., 2011).  
In an attempt for non-invasive cancer diagnosis, Li et al, (2017) has successfully 
isolated six aptamer candidates that distinguishes the serum between lung cancer 
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patients and healthy individuals using an aptamer-based PCR assay. The method utilises 
selection of aptamers from the magnetic beads-immobilized serum proteins from the 
lung cancer patients and negative selections with those of healthy individuals, thus 
giving rise to populations of aptamers specifically targeting the surface biomarkers 
present in the diseased serum (Li et al., 2017a).  
Aptamers were also developed towards the pathological assessment of tissues. 
Ahirwar et al. (2016) demonstrated successful histochemistry and cytochemistry 
staining for Estrogen receptor alpha in breast tissues using their DNA aptamer . Zeng 
et al. (2010) demonstrated the detection of the CD30 biomarker in formalin-fixed 
paraffin embedded tissue sections using an RNA aptamer in a lower antigen retrieval 
temperature of 37 °C and a shorter incubation time of 20 minutes compared to the tested 
antibody which require 95 °C antigen retrieval temperature and a 90 minutes incubation 
time .  
1.5 Aptamers in Therapeutics 
The ligand binding property of aptamers provides potential antagonistic abilities that 
endows them with therapeutic potential. At the moment, one aptamer has successfully 
been commercialized (Kaur et al., 2018; Morita et al., 2018; Ng et al., 2006). Macugen 
is the only FDA approved aptamer that was developed for the treatment of age-related 
macular degeneration (AMD). The aptamer serves as an anti-angiogenic drug by 
antagonizing Vascular Endothelial Growth Factor (VEGF) 165 isoform (Ng et al., 
2006). It is intravitreally injected into the eyes in a 0.3 mg dose once every six weeks 
and is approved for use in several countries including Australia, Brazil, Canada, Europe 
and the United States (Kaur et al., 2018).  
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Studies on Programmed Cell Death Protein 1 (PD-1) and Cytotoxic T 
Lymphocyte Antigen-4 (CTLA-4) have elucidated their role in the eventual 
deactivation of T-cell response that limits their action against tumours (Freeman et al., 
2000; Krummel et al., 1995). From this emerged a derivative of immunotherapy called 
T-cell checkpoint therapy which utilised monoclonal antibodies to antagonize these 
proteins that resulted in enhanced anti-tumour response (Sharma et al., 2015; Keir et al., 
2008; Okazaki et al., 2007; Leach et al., 1996). The edge aptamer has over antibodies 
has sparked an interest to utilise aptamers as potential antagonists against these proteins 
(Huang et al., 2017; Lai et al., 2016). Lai et al. (2016) showed inhibition of PD-1 protein 
binding from its ligand PDL-1 using their aptamer which resulted in supressed in vivo 
tumour growth as well as a matching immune profile seen with monoclonal anti PD-1 
antibody treatment, such as increased CD4+ and CD8+ infiltration with elevated levels 
of cytokines . Similarly, Huang et al. (2017) generated a CTLA-4 DNA aptamer 
antagonist which demonstrated identical potency as anti CTLA-4 monoclonal antibody 
in a mouse model with a lesser degree of weight loss in the mouse .  
As molecular recognition elements, aptamers are also utilized in delivering 
therapeutic cargo to target cells. Gray et al. (2018) harnessed the intrinsic properties of 
aptamers by selecting aptamers capable of internalizing into prostate cancer cells 
without affecting the normal prostate cells . They demonstrated the potency of aptamer-
based targeted chemotherapy by chemically conjugating cytotoxic agents to their 
aptamer and this tool was able to specifically kill malignant prostrate cells in vitro and 
reduced tumour growth in vivo (Gray et al., 2018). Additionally, they showed the unique 
capability to tune the cytotoxicity level using a nucleic acid ‘antidote’ that destabilizes 
the aptamer structure through complementary base pairing, thus deactivating its binding 
ability (Gray et al., 2018; Rusconi et al., 2004).  
9 
 
1.6 Pituitary Tumour Transforming Gene 1 (PTTG1) 
Human Pituitary Tumour Transforming Gene 1 (PTTG1) is a proto-oncogene with an 
open reading frame of 609 bp that encodes for a 23 kDa protein (Kakar, 1999; 
Domínguez et al., 1998). Rat PTTG1 mRNA from rat pituitary tumour cells was initially 
found to be highly expressed and the protein was capable of inducing cellular 
transformation both in vitro as well as in vivo. In 1998, the human homolog of rat 
PTTG1 was structurally identified and demonstrated evidence of transcriptional activity 
(Domínguez et al., 1998; Pei et al., 1997). Southern blot analysis revealed two 
additional gene homologues namely PTTG2 (576 bp) with 91 % similarity and PTTG3 
(609 bp) with 89 % similarity to PTTG1. However, their expression levels are 
determined to be nil or very low with unclear significance nor roles determined yet for 
these homologues (Zhou, 2013; Chen et al., 2000). The expression level of PTTG1 is 
weak or undetected in normal cells such as pancreas, brain, lung, colon, and small 
intestine but was found to be high in actively proliferating organs such as the adult testis 
and thymus (Kakar, 1999; Zhang et al., 1999; Domínguez et al., 1998). PTTG1 was 
found to be localized in both nucleus and cytoplasm (Mu et al., 2003; Zhang et al., 1999; 
Domínguez et al., 1998).  
PTTG1 is extremely hydrophilic and consists of an acidic transactivation 
domain at the C-terminus, a DNA binding domain and a basic N-terminus (Zhou, 2013; 
Kakar et al., 1999; Zhang et al., 1999) (Figure 1.2). The transactivation domain involves 
SH3-binding sites and together with the DNA binding domain, are responsible for 
PTTG1 to modulate cellular proliferation, transformation and exhibit transactivation 
effects (Boelaert et al., 2004; Pei, 2001). A destruction (D) box and KEN box, involved 
in the degradation of PTTG1, are situated in the N terminus (Zou et al., 1999). PTTG1 
falls into the family of proteins categorized as intrinsically disordered proteins (IDP) 
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(Sánchez-Puig et al., 2005; Kakar et al., 2001). It is natively unfolded and devoid of a 
tertiary structure with a minimal secondary structure consisting of only a small amount 
of poly-(L-proline) type II helix (Chu et al., 2014; Csizmok et al., 2008; Sánchez-Puig 
et al., 2005).  
Initially recognized as an oncoprotein, Zou et al. functionally identified PTTG1 
to be linked to the cell cycle regulation as the Separase inhibitor or Securin (Zou et al., 
1999). An upsurge of PTTG1 mRNA expression during the cell cycle S phase that peaks 
at the S-G2 transitions and declines thereafter, suggests that PTTG1 adopts a cell cycle 
dependent expression (Vlotides et al., 2006). PTTG1 has been shown to lead towards 
the accumulation of inactive Separase at the nucleus which is in line with its role as the 
Separase inhibitor predominantly throughout the cell cycle (Han et al., 2013; Hornig et 
al., 2002; Zur, 2001; Nasmyth et al., 1999). At the onset of anaphase, PTTG1 is targeted 
for proteasomal degradation which allows Separase to create a loss of chromosome 
cohesion resulting in sister chromatids separation (Han et al., 2013; Zur, 2001; Nasmyth 
et al., 1999). Apart from that, PTTG1 was shown to have a role for the transition of cells 
into G1/S and G2/M phases by interaction with the transcription factor Sp1. In another 
study, it was found out that PTTG1 affects the stability of cyclin B, compelling the 
modulation of cell cycle timing into M phase in mouse oocytes (Marangos et al., 2008; 
Tong et al., 2007).  
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Figure 1.2 Schematic illustration of PTTG1 Protein Structure  
PTTG1 consists of 202 amino acids. At the N-terminal, a KEN box is situated at the 9 
to 11 aa while a D Box is situated at the aa residues 61 to 68. A DNA binding domain 
is present from aa residue 60 to 118 while the transactivation domain is located at the 
aa residue 119 to 164. SH3 binding sites were located at residues 51 to 54 and 164 to 
173 (Tong et al., 2009; Tong et al., 2008; Vlotides et al., 2007). 
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1.7 PTTG1 as a Biomarker for Cancer Diagnostics and Prognostics 
With its role in maintaining chromosome stability and its demonstration of cellular 
transformation effects, PTTG1 overexpression serves as a potential biomarker in the 
diagnosis of various cancers such as multiple myeloma, clear cell renal cell carcinoma, 
non-small cell lung cancer, hepatocellular carcinoma, breast cancer, gastric cancer, and 
adrenocortical carcinoma  (Romero Arenas et al., 2018; Wang et al., 2016; Xiea et al., 
2016; Xu et al., 2016; Noll et al., 2015; Wei et al., 2015; Fujii et al., 2006; Thompson 
et al., 2005; Jallepalli et al., 2001). Similarly, PTTG1 was also found to be 
overexpressed in various cancerous cell lines such as T lymphocyte cell Jurkat, 
colorectal carcinoma HT-29, HCT-116, SW480 and SW620, cervical carcinoma HeLa, 
breast carcinoma MCF-7, Burkitt’s lymphoma Raji, and promyelocytic leukemia HL-
60 (Ren et al., 2017; Kakar, 1999; Zhang et al., 1999). 
Several studies have indicated that the level of PTTG1 overexpression resulted 
in poor prognosis that stems from increased aggressiveness in the tumour behaviour. In 
a study comprising 210 laryngeal carcinoma patients, 185 showed increased PTTG1 
expression in the laryngeal cancer tissues when compared to their carcinoma-adjacent 
normal laryngeal tissues. The increased expression implied association with lymph node 
metastasis, tumour grade and level of malignancy (Ma et al., 2018). In colorectal cancer, 
PTTG1 overexpression serves as an indicator for invasiveness and unfavourable 
prognosis as the invasive cancer cells had high levels of PTTG1 and patients with these 
high PTTG1 expressing tumours had a lower overall survival rate (Ren et al., 2017; 
Heaney et al., 2000).  
Ishitsuka et al. (2013) however found PTTG1 to be more significant as a 
proliferation marker in cutaneous squamous cell carcinoma. They found the levels of 
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PTTG1 expression does not correlate with the TNM staging, tumour thickness, clinical 
stage and high-risk clinicopathologic features but positively correlates with the level of 
expression for Ki67, a known proliferation marker in cutaneous squamous cell 
carcinomas (Ishitsuka et al., 2013).  
Apart from the overexpression, the subcellular localization of PTTG1 may 
impart additional prognostic value. In a case study involving 470 breast cancer tissue 
specimens, Gurvits et al. (2016) found PTTG1 staining to be high and predominantly 
cytoplasmic in aggressive cases particularly triple-negative carcinomas . In addition, 
patients with sparse PTTG1 cytoplasmic staining survived 11.2 years after diagnosis 
however, for a majority of the patients with high PTTG1 cytoplasmic staining, the 
expected survival time was 4.2 years after diagnosis (Gurvits et al., 2016). 
1.8 PTTG1 as a Target for Cancer Therapeutics 
PTTG1 has been demonstrated to have potent contribution towards tumorigenicity. 
Genetic instability is one of the tumorigenic factors resulting from PTTG1 
overexpression (Hsu et al., 2010; Jallepalli et al., 2001). As a securin, PTTG1 
inactivates separase until the onset of anaphase where the latter is degraded. As a result 
of this degradation, Separase is liberated to promote sister chromatid separation. Cells 
with abnormal PTTG1 levels therefore demonstrated anomalies in their cell cycle 
regulation along with the occurrences of deformed chromosome masses, prolonged 
metaphase to anaphase transition interval and reduced levels of Separase (Hsu et al., 
2010; Jallepalli et al., 2001).  
The acidic C-terminal hinted the role of PTTG1 as a transcription factor upon 
experimentation by fusion with a heterologous DNA-binding domain (Domínguez et 
al., 1998). It was later shown that PTTG1 demonstrated transactivation activity and was 
14 
 
even described to exhibit properties as a “global transcription factor” due to its 
capability to bind to 746 gene promoters (Tong et al., 2007; Pei, 2001). In 2001, using 
DNA array and inducible PTTG1 expression on HeLaS3 cells, Pei found that PTTG1 
overexpression rapidly induced the transcription of c-myc oncogene within 6 hours by 
directly interacting with its promoter region. The increase in c-myc expression resulted 
in increased cellular proliferation and colony formation (Pei, 2001).  
Apart from that, PTTG1 was found to contribute to the metastasis of breast 
cancer by transactivation of CXCR2 (Ruan et al., 2012). The CXCR2/p21 senescence 
pathway was found to be activated upon direct transactivation of CXCR2 by PTTG1. 
Breast cancer cells with ectopically overexpressed PTTG1 that possessed a defective 
senescence mechanism had demonstrated an increase in metastasis. It was found that, 
if on the other hand, the senescence pathway is intact, PTTG1 overexpression leads the 
cells into senescence and restricted the oncogenic potential of PTTG1. Interestingly, 
these senescent cells were found to create an inflammatory reaction which recruited 
macrophages and in turn promoted the metastasis of surrounding non-senescent tumour 
cells (Chen, 2013). In this study, the interaction between PTTG1 and a CXCR2 
enhancer sequence will be used as a model to probe the therapeutic potential of the 
aptamer. 
p53 is a tumour suppressor protein which partakes physiological roles towards 
the suppression of cancer. In an attempt to study the tumorigenesis of PTTG1, Bernal 
et al. demonstrated that PTTG1 interacts with p53 and hindered its DNA binding ability 
in vitro and further confirmed this using the luciferase reporter assay. Furthermore, 
decreased transactivating action of p53-induced promoters (BAX, SFN, and CDKN1A) 
upon PTTG1 overexpression was found, which resulted in the decrease in p53-induced 
apoptosis of mouse fibroblast NIH3T3 cells (Bernal et al., 2002). 
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Knockdown of PTTG1 have been demonstrated to lead towards the suppression 
of cancer. Using PTTG1 targeting siRNA, Kakar et al. found that PTTG1 knockdown 
had reduced colony forming abilities in lung cancer cells in vitro and implantation of 
these cells in vivo demonstrated suppressive effects on the tumour growth in terms of a  
prolonged time for tumour formation and significantly reduced tumour mass (Kakar et 
al., 2006). Similarly, miRNAs targeting PTTG1 was shown to have inhibited cell 
viability and motility as well as induced apoptosis in tumour cells in vitro and in vivo 
(Liang et al., 2015; Wang et al., 2013). 
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1.9 Objectives of the Study 
The generation of the aptamer can facilitate the development of aptamer-based 
diagnostic and therapeutic applications of PTTG1. Therefore, the objectives of this 
study are as follows: 
i) To express and purify recombinant PTTG1 
a) Construction of pET14-PTTG1 plasmid 
b) Expression and purification of recombinant PTTG1 
c) Protein identity confirmation with western blot assay using monoclonal 
antibody 
d) Protein folding analysis to compare dialyzed and denatured PTTG1 
e) Functional protein-protein interaction to confirm successful folding of PTTG1 
ii) To generate RNA aptamer that has high binding affinity and specificity against 
recombinant PTTG1 
a) Execution of the SELEX cycles to isolate RNA aptamer against recombinant 
PTTG1 
b) Cloning and sequence analysis of aptamer pool 
c) Binding analysis of the sequence classes using nitrocellulose filter binding 
assay to search for the RNA aptamer candidate 
d) Dissociation constant and secondary structure determination of the candidate 
RNA aptamer against PTTG1 
e) Interaction analysis between the RNA aptamer, monoclonal antibody and 
PTTG1 protein 
iii) To analyse the diagnostic potentiality of the RNA aptamer  
a) Development of Aptamer-linked immunosorbent assay (ALISA) 
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b) Development of Aptamer-based dot blot assay and aptamer-based western 
blot assay 
c) Development of Aptahistostaining assay with MCF-7 and HeLa cell lines 
iv) To study the potential functionality of the RNA aptamer towards therapeutic 
applications 
a) To execute in vitro competitive filter binding assay of PTTG1 and its known 
binding target, CXCR2 enhancer sequence and the RNA aptamer 
b) To analyse the potentiality of the RNA aptamer to antagonize the interaction 
between PTTG1 and CXCR2 enhancer sequence 
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CHAPTER 2 
EXPRESSION AND PURIFICATION OF RECOMBINANT PTTG1 FOR RNA 
APTAMER SELECTION 
2.1 Introduction  
PTTG1 is a 23 kDa intrinsically disordered oncoprotein that lacks a stable tertiary 
structure and contains minimal secondary structure (Sánchez-Puig et al., 2005; Kakar, 
1999; Domínguez et al., 1998). PTTG1 is also alternatively known as human Securin, 
due to its role in the cell cycle regulation as an inhibitor of Separase (Gurvits et al., 
2016; Castilla et al., 2014; Chu et al., 2014; Han et al., 2013; Moreno-Mateos et al., 
2011; Zou et al., 1999). This oncoprotein has been implicated from its overexpression, 
onto the tumorigenicity of many cancers and as such is a highly potential cancer 
biomarker and therapeutic target (Romero Arenas et al., 2018; Ren et al., 2017; Wang 
et al., 2016). Development of compounds, peptides or ligands that can potentially 
antagonize PTTG1 is highly favourable, and this would require a highly purified 
protein. Thus, to generate an aptamer with high specificity and affinity to PTTG1 as 
well as for subsequent aptamer-based assays development, it is prudent and cost 
effective to produce the protein in-house which can cater to the relevant purity and yield 
requirements. 
PTTG1 gene was cloned from a GST-tagged plasmid, which bears the gene, into 
a 6X His-tagged bacterial expression plasmid (pET14b). Subsequent to this, optimized 
expression and purification recombinant PTTG1 in a bacterial expression system was 
carried out. Western blot to identify and confirm the protein identity was performed. 
Protein folding analysis via intrinsic florescence and functional interaction using GST 
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pulldown assay with a known GST-fused PTTG1 binding partner, p53 was performed 
to ensure the purified PTTG1 is amenable for SELEX. 
 
2.2 Materials and Methods 
2.2.1 Isolation of PTTG1 Gene via PCR Amplification 
PTTG1 gene was isolated via PCR amplification from the pGEX-PTTG1 plasmid (A 
gift from Prof Ji-Hshiung Chen, Tzu Chi University, Taiwan) (Appendix B) using the 
forward primer PTTG1NdeI-F (5’-GAG Cca tat gGC TAC TCT GAT CTA TG-3’) and 
the reverse primer PTTG1XhoI-R (5’-GAG Cct cga gTT AAA TAT CTA TGT CAC 
AG-3’). The forward primer and the reverse primer contain NdeI restriction site and 
XhoI restriction site, respectively (restriction sites are represented with small caps and 
underlined). PCR amplification was carried out in a 20 μL reaction mixture containing 
1X PCR buffer (10 mM Tris-HCl pH 8.8, 50 mM KCl, 0.08 % (v/v) Nonidet P40) 
(Fermentas, Burlington, Canada), 1.5 mM MgCl2 (Promega Corporation, Madison, 
USA), 0.2 mM dNTPs (Promega Corporation, Madison, USA), 5 U of Taq DNA 
polymerase (Fermentas, Burlington, Canada), and 0.1 μM of each primers. The PCR 
was performed on the T-100 PCR thermocycler (Bio-Rad Laboratories, Hercules, USA) 
with parameters for PCR cycles as follow: an initial denaturation at 95 °C for 60 s 
followed by 30 cycles of 30 s denaturation at 95 °C, 30 s annealing at 60 °C, 30 s 
extension at 72 °C and a final elongation of 120 s at 72 °C.  
2.2.2 Agarose Electrophoresis 
Following PCR, 5 μL of the PCR product was added with 1 μL of 6X Blue/Orange 
DNA loading dye (10 mM Tris-HCl pH 7.5, 50 mM EDTA pH 8.0, 0.4 % orange G, 
0.03 % bromophenol blue, 0.03 % xylene cyanol FF, 15 % Ficoll® 400) (Promega 
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Corporation, Madison, USA) which contained 0.5 μg/mL of ethidium bromide (Sigma-
Aldrich, St. Louis, USA). The PCR product was run on a 2 % agarose gel (Promega 
Corporation, Madison, USA) using a mini gel apparatus (Bio-Rad Laboratories, 
California, USA) with 1X TAE buffer (40 mM Tris-acetate, 1 mM EDTA) at 100 V for 
30 min. The gel was visualized using the Gel Doc™ XR+ Gel documentation system 
(Bio-Rad Laboratories, California, USA). The amplicon size was confirmed with a 100 
bp DNA ladder (Promega Corporation, Madison, USA). 
2.2.3 Cloning of PTTG1 Gene into TOPO TA cloning vector 
The fresh PCR product was cloned into pCR@2.1 cloning vector using TOPO TA 
cloning kit (Thermo Fisher Scientific, Massachusetts, USA) as per manufacturer’s 
protocol. The reaction mixture contains 2 μL of fresh PCR product, 1 μL of salt solution 
(1.2 M NaCl and 0.06 M MgCl2), 2 μL ddH2O, and 1 μL of pCR@2.1 cloning vector. 
The mixture was incubated for 30 min at RT. 
2.2.4 Transformation of TOPO-PTTG1 plasmid into E.coli TOP10 cells 
Chemically competent E.coli TOP10 cells (Catalogue number: C404010) (Invitrogen, 
Carlsbad, USA) were thawed on ice. The prepared ligation mixture was incubated with 
the competent cells on ice for 30 min. The bacterial cells were then subjected to heat 
shock in a water bath (Fisher Scientific, Hampton, USA) at 42 °C for 45 s and 
immediately incubated on ice. One milliliter of Luria Bertani (LB) medium (Pronadisa, 
Madrid, Spain) was added and the cells were incubated at 37 °C with shaking at 200 
rpm for 60 min (Thermo Scientific, Massachusetts, USA). Meanwhile, 50 μL of 40 
mg/mL of X-Gal (Takara Bio, Shiga, Japan) and 50 μL of 100 mM IPTG (Fermentas, 
Burlington, Canada) were spreaded on LB agar plates (Pronadisa, Madrid, Spain) 
containing 50 μg/mL Ampicillin (Roche Diagnostics GmbH, Mannheim, Germany). 
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After incubation, the tubes were centrifuged for 2 min at 13000 x g (Thermo Scientific, 
Massachusetts, USA) and 1 mL of the LB broth supernatant was removed from the tube. 
The cell pellets were resuspended in the remaining medium (approximately 200 μL) 
and was plated onto the selection plates before incubation at 37 °C overnight. 
2.2.5 Dual Restriction Enzyme Digestion of Vector and Insert 
Reaction mixtures were prepared for the restriction enzyme digestion of pET14b vector 
(Merck KGaA, Darmstadt, Germany) and TOPO TA cloning vector carrying the PTTG1 
gene. The reaction mixtures contains 15 μL of water, 2 μL 10X FastDigest reaction 
buffer (Thermo Scientific, Massachusetts, USA), 5 U FastDigest NdeI enzyme (Thermo 
Scientific, Waltham, USA), 5 U FastDigest XhoI enzyme (Thermo Scientific, 
Massachusetts, USA) and 1000 ng of vector or 1000 ng of insert PTTG1 DNA fragment. 
The reaction mixture was incubated at 37 °C for 5 min. 
2.2.6 Gel Purification of Digested Fragments 
A few microliters of the digested fragments were mixed with 6X loading dye and 
subjected to agarose electrophoresis (2 % agarose gel for PTTG1 gene fragment and 0.8 
% agarose gel for pET14b plasmid) at 100 V for 30 min. The bands were visualized and 
excised under a UV transilluminator (Fisher Scientific, Massachusetts, USA). The DNA 
fragments were then purified using Roche High Pure PCR Product Purification Kit 
(Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s 
protocol. The excised gel was weighed in a 1.5 mL microcentrifuge tube and Binding 
Buffer was added accordingly. The mixtures were incubated in a heating block 
(Eppendorf, Hamburg, Germany) at 60 °C for 60 min. The contents were transferred 
into filter tubes housed within the collection tubes and centrifuged at 13000 x g for 2 
min with the flow through subsequently discarded. Next, 700 μL of Wash buffer was 
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added and centrifuged at 13000 x g for 1 min. The flow through was discarded and the 
centrifugation was repeated once to remove the residual wash buffer. Hundred 
microliters of the elution buffer were added, and the tubes were centrifuged at 13000 x 
g for 1 min. The purified DNA was quantified using a spectrophotometer (Implen Inc, 
Westlake Village, USA).  
2.2.7 Ligation of the Insert and pET14b Vector 
The ligation reaction mixture was prepared which contains 1X T4 Ligation Buffer 
(Thermo Scientific, Massachusetts, USA), 5 U T4 DNA Ligase (Thermo Scientific, 
Massachusetts, USA), 200 ng vector DNA, 1000 ng insert DNA and topped up to 20 
μL with ddH2O. The reaction mixture was incubated overnight at 4 °C. The cells were 
transformed into chemically competent E. coli TOP10 cells by heat shock and 
subsequently cultured in a shaking incubator set at 200 rpm, 37 °C for 90 min. The cells 
were plated on a LB Agar plate containing 50 μg/mL Ampicillin (Roche Diagnostics 
GmbH, Mannheim, Germany). The plate was incubated overnight at 37 °C. 
2.2.8 pET14-PTTG1 Plasmid Extraction  
A single colony was picked and inoculated into 4 mL of LB broth containing 50 μg/mL 
Ampicillin. The culture was incubated overnight with shaking at 200 rpm, 37 °C. The 
overnight culture was centrifuged at 10000 x g and the supernatant was discarded. The 
pET14-PTTG1 plasmid was extracted using the Roche High Pure Plasmid Isolation Kit 
(Roche Diagnostics GmbH, Mannheim, Germany) according to manufacturer’s 
protocol. The pellet was resuspended in 250 μL of Resuspension Buffer containing 
RNAse and incubated for 5 min at RT. Next, 250 μL of Lysis buffer was added and the 
mixture was gently mixed by inverting. It was then incubated for 5 min on ice before 
addition of 250 μL chilled Binding buffer. The reaction mixture was mixed gently by 
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inverting and centrifuged at 13000 x g for 15 min. The supernatant was transferred to 
the filter tube housed in the collection tube and centrifuged at 13000 x g for 1 min where 
the flow through was discarded thereafter. Next, 700 μL of Wash buffer was added and 
centrifuged at 13000 x g for 1 min. The tube was centrifuged again to remove residual 
wash buffer. 100 μL of elution buffer was added and the plasmid was eluted by 
centrifugation at 13000 x g for 1 min. The plasmid DNA was quantified using a 
spectrophotometer (Implen Inc, Westlake Village, USA). 
2.2.9 Plasmid Sequencing of pET14-PTTG1  
Sequencing of the plasmid (0.5 μg) was carried out using 0.5 μM of PTTG1NdeI-F 
primer by Apical Scientific Sdn Bhd.  
2.2.10 Transformation of pET14-PTTG1 for Protein Expression 
Rare codons were found on the PTTG1 gene sequence which could affect the protein 
expression level due to codon bias (Refer Section 2.3.2 for detailed explanation). 
Therefore, Rosetta 2(DE3)pLysS strain was selected due to its possession of the 
pRARE2 plasmid which encodes for the rare tRNAs. On the other hand, the 
NiCo21(DE3) strain was used for expression to help in obtaining better purity as 
previous studies have demonstrated PTTG1 purification was often co-purified with high 
molecular weight proteins (Refer Section 2.3.3 for detailed explanation). For the 
transformation process, 1 μL of the purified pET14-PTTG1 plasmid was transformed 
into chemical competent Rosetta 2(DE3)pLysS cells (Catalogue number: 71403) 
(Merck KGaA, Darmstadt, Germany) (Genotype: F- ompT hsdSB(rB- mB-) gal dcm 
(DE3) pLysSRARE2 (CamR) ) and NiCo21(DE3) cells (Catalogue number: C2529H) 
(Genotype: can::CBD fhuA2 [lon] ompT gal (λ DE3) [dcm] arnA::CBD slyD::CBD 
glmS6Ala ∆hsdS λ DE3 = λ sBamHIo ∆EcoRI-B int::(lacI::PlacUV5::T7 gene1) i21 
24 
 
∆nin5) (New England Biolabs, Massachusetts, USA) by heat shock. The NiCo21(DE3) 
strain is a genetically engineered strain with improved IMAC purity to aid in protein 
purification due to co-purification of host protein issue in PTTG1 purification. The 
transformed cells were incubated in a shaking incubator set to 200 rpm at 37 °C for 90 
min and 100 μL of the cell suspension were plated on a LB Agar plate containing 50 
μg/mL Ampicillin (Roche Diagnostics GmbH, Mannheim, Germany) and 25 μg/mL 
Chloramphenicol (Merck KGaA, Darmstadt, Germany). The plate was incubated 
overnight at 37 °C. 
2.2.11 PTTG1 Protein Expression via IPTG induction 
Following transformation, a single colony was picked and inoculated into 4 mL LB 
broth containing 50 μg/mL Ampicillin and 25 μg/mL Chloramphenicol. The culture was 
incubated overnight with shaking at 200 rpm, 37 °C. One milliliter of the overnight 
culture was inoculated into 100 mL of LB broth containing 50 μg/mL Ampicillin and 
25 μg/mL Chloramphenicol. Optical density at 600 nm (OD600) of the culture was 
monitored using the Bio-photometer spectrophotometer (Eppendorf, Hamburg, 
Germany). Once the OD600 reached 0.6, a final concentration of 0.5 mM of IPTG was 
added to the culture and further incubated. For time course analysis of the protein 
expression, 1 mL of the culture was taken at one-hour intervals for a total of 20 hours 
and pelleted by centrifugation at 10000 x g for 1 min. The pellets were boiled in 5X 
reducing SDS Sample Buffer for 10 min and subjected to SDS PAGE electrophoresis.  
2.2.12 SDS PAGE Electrophoresis and Coomassie Blue staining  
Protein samples were re-suspended in 5X reducing SDS PAGE Sample Buffer (100 mM 
Tris-HCl pH 6.8, 10 % SDS, 50 % glycerol, 5 % Beta-mercaptoethanol, 0.05 % 
bromophenol blue) and heated for 10 min at 95 °C. Samples were resolved on 12 % 
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(w/v) polyacrylamide gel (Appendix L) at 100 V for 60 min in 1X SDS Running Buffer 
(25 mM Tris pH 8.3, 0.1 % SDS, 192 mM glycine). Subsequently, the gel was subjected 
to 0.1 % Coomassie Blue R250 staining solution (Bio-Rad Laboratories, California, 
USA) which contained 0.1 % Coomassie brilliant blue, 30 % methanol, 10 % acetic 
acid for 1 hour followed by overnight destaining in destaining solution which contained 
30 % methanol and 10 % acetic acid. 
2.2.13 PTTG1 Protein Purification 
High molecular weight proteins were often co-purified with PTTG1 purification on a 
bacterial expression system as seen in other published works (Hsu et al., 2010; Chiriva-
Internati et al., 2008; Csizmok et al., 2008; Kakar et al., 2001). Therefore, purification 
with the NiCo21(DE3) strain (genetically engineered strain for higher purity in IMAC 
purification) and a denaturing purification with urea was employed to aid in obtaining 
high purity PTTG1. 
2.2.13(a) PTTG1 Protein Purification from Rosetta 2(DE3)pLysS cells 
After protein expression via IPTG induction, the cells were pelleted by centrifugation 
at 10000 x g, 4 °C for 15 min (Kubota, Tokyo, Japan). The pellet was re-suspended in 
cold denaturing Binding Buffer (20 mM Tris pH 8.6, 8 M Urea, 150 mM NaCl, 10 % 
Glycerol, 1.5X Protease Inhibitor Cocktail EDTA-free) (Roche Diagnostics GmbH, 
Mannheim, Germany) and lysed by bead-beating (MP Biomedicals, California, USA) 
using 0.1 mm glass beads (BioSpec, Oklahoma, USA) for 15 s followed by chilling on 
ice for 30 s intervals for a total of 8 times. The lysate was centrifuged at 10000 x g for 
10 min at 4 °C, and the supernatant was collected and re-suspended in chilled Binding 
Buffer containing pre-equilibrated Talon Resin (Clontech, California, USA) using a 
rotator for 60 min at 4 °C. The resin was washed five column volumes with cold 
